Margarine phytosterols decrease the secretion of atherogenic lipoproteins from HepG2 liver and Caco2 intestinal cells.
Several studies in humans have demonstrated the hypocholesterolemic effect of plant sterol consumption. It is unclear whether plant sterols regulate lipoprotein metabolism in the liver and intestines, thereby decreasing the levels of circulating atherogenic lipoproteins. We investigated the effect of the three main phytosterols: stigmasterol, campesterol, and beta-sitosterol on lipoprotein production in HepG2 human liver cells and Caco2 human intestinal cells and the mechanisms involved. Cells were incubated for 24h with 50 micromol/L of the different phytosterols or 10 micromol/L of atorvastatin. Very low-density lipoprotein levels (measured by apolipoprotein (apo) B100) in HepG2 cells and chylomicron levels (measured by apoB48) in Caco2 cells were measured using western blotting. Intracellular cholesterol levels were measured using gas chromatography. Analysis was carried out using Student's t-test and ANOVA. Secretion levels of apoB100 significantly decreased by approximately 30% after incubation with all phytosterols compared to control. In addition, cholesterol ester (CE) concentrations significantly decreased when HepG2 cells were incubated with the phytosterols compared to control cells. Secretion of apoB48 from intestinal cells significantly decreased by 15% with stigmasterol, 16% with campesterol and 19% beta-sitosterol compared to control. Collectively the data suggests that plant sterols limit lipid (CE) availability in cells. Decreases in circulating levels of LDL and chylomicron remnants seen in humans with the consumption of margarine phytosterols are possibly due to their effect on lipid production in cells and would therefore reduce the risk of developing cardiovascular disease.
Ho
Suleen S
SS
Department of Nutrition, Dietetics and Food Science, School of Public Health, Curtin University, Perth, Western Australia 6845, Australia.
Pal
Sebely
S
D000924:Anticholesteremic Agents / Q000494:pharmacology; D053299:Apolipoprotein B-100; D053283:Apolipoprotein B-48; D001055:Apolipoproteins B / Q000378:metabolism*; D050197:Atherosclerosis / Q000188:drug therapy* / Q000378:metabolism; D000069059:Atorvastatin; D018938:Caco-2 Cells; D006528:Carcinoma, Hepatocellular; D002784:Cholesterol / Q000031:analogs & derivatives* / Q000378:metabolism / Q000494:pharmacology; D004357:Drug Synergism; D020895:Enterocytes / Q000187:drug effects / Q000378:metabolism; D022781:Hepatocytes / Q000187:drug effects / Q000378:metabolism; D006538:Heptanoic Acids / Q000494:pharmacology; D006801:Humans; D008113:Liver Neoplasms; D008383:Margarine; D010840:Phytosterols / Q000494:pharmacology*; D011758:Pyrroles / Q000494:pharmacology; D012855:Sitosterols / Q000494:pharmacology; D013265:Stigmasterol / Q000494:pharmacology
D000924:Anticholesteremic Agents; D053299:Apolipoprotein B-100; D053283:Apolipoprotein B-48; D001055:Apolipoproteins B; D006538:Heptanoic Acids; D010840:Phytosterols; D011758:Pyrroles; D012855:Sitosterols; C021273:campesterol; C025473:gamma-sitosterol; D008383:Margarine; D002784:Cholesterol; D013265:Stigmasterol; D000069059:Atorvastatin